<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03309514</url>
  </required_header>
  <id_info>
    <org_study_id>NGN-9076</org_study_id>
    <nct_id>NCT03309514</nct_id>
  </id_info>
  <brief_title>Transplantation of Neural Stem Cell-Derived Neurons for Parkinson's Disease</brief_title>
  <official_title>Clinical Investigation of Transplantation of Neural Stem Cell-derived Neurons for the Treatment of Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeuroGeneration</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeuroGeneration</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective study to demonstrate the safety and efficacy of differentiated&#xD;
      neurons-derived from adult CNS progenitors cells transplanted in selected patients with&#xD;
      Parkinson's disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Motor UPDRS</measure>
    <time_frame>6 months</time_frame>
    <description>UPDRS Motor scale</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intracerebral microinjections</intervention_name>
    <description>Stereotactic delivery of cell suspension into basal ganglia structures</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to give informed consent prior to study&#xD;
&#xD;
          2. Male or Female with Diagnostic Criteria of Parkinson's disease&#xD;
&#xD;
          3. Age 35 to 85 years old&#xD;
&#xD;
          4. Parkinson's disease not due to trauma, infection, brain tumor, cerebrovascular disease&#xD;
&#xD;
          5. Hoehn and Yahr Stage III or IV&#xD;
&#xD;
          6. Parkinson's disease observed in the absence of:&#xD;
&#xD;
               -  Oculomotor palsy&#xD;
&#xD;
               -  Cerebellar sign&#xD;
&#xD;
               -  Orthostatic hypotension (drop greater than 20mmHg in mean pressure)&#xD;
&#xD;
               -  Pyramidal sign&#xD;
&#xD;
               -  Amyotrophy&#xD;
&#xD;
          7. Good general health or stable medical condition well controlled, without&#xD;
             contraindications to anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with severe dementia and brain atrophy on MRI&#xD;
&#xD;
          2. Patients with severe hypertension; renal, liver, cardiac or other major organ disease;&#xD;
             coagulopathy; cancer; other significant systemic illnesses; hepatitis, HIV&#xD;
&#xD;
          3. Patients older than 85 or younger than 35&#xD;
&#xD;
          4. Patients who withhold informed consent&#xD;
&#xD;
          5. Patients with a history of alcohol or drug abuse&#xD;
&#xD;
          6. Sexually active women of childbearing potential without adequate form of birth control&#xD;
&#xD;
          7. Evidence of abnormal coagulation or anticoagulant therapy&#xD;
&#xD;
          8. Pregnancy or lactation&#xD;
&#xD;
          9. History of seizure disorders or current use of antiepileptic medication&#xD;
&#xD;
         10. Severe cognitive impairment&#xD;
&#xD;
         11. Clinically significant laboratory abnormality&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 10, 2017</study_first_submitted>
  <study_first_submitted_qc>October 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2017</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>NeuroGeneration</investigator_affiliation>
    <investigator_full_name>Michel F. Levesque, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

